Dina Pietrangelo

491 total citations
4 papers, 345 citations indexed

About

Dina Pietrangelo is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dina Pietrangelo has authored 4 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Oncology. Recurrent topics in Dina Pietrangelo's work include Cancer Immunotherapy and Biomarkers (2 papers), Advanced Breast Cancer Therapies (2 papers) and Protein Degradation and Inhibitors (2 papers). Dina Pietrangelo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (2 papers), Advanced Breast Cancer Therapies (2 papers) and Protein Degradation and Inhibitors (2 papers). Dina Pietrangelo collaborates with scholars based in United States, Greece and Canada. Dina Pietrangelo's co-authors include Jasgit C. Sachdev, Andréa Varga, Antoinette R. Tan, Emilie M.J. van Brummelen, Sanatan Saraf, Christophe Le Tourneau, Vassiliki Karantza, Sherene Loi, Roberto Salgado and Jean‐Pierre Delord and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Dina Pietrangelo

4 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dina Pietrangelo United States	3	311	125	124	71	40	4	345
P. Schmid United Kingdom	3	287 0.9×	142 1.1×	67 0.5×	113 1.6×	49 1.2×	4	343
A. Swat Switzerland	4	305 1.0×	135 1.1×	89 0.7×	112 1.6×	45 1.1×	6	354
Michela Palleschi Italy	9	189 0.6×	133 1.1×	38 0.3×	75 1.1×	75 1.9×	46	281
Elza C. de Bruin United Kingdom	6	171 0.5×	112 0.9×	43 0.3×	140 2.0×	101 2.5×	8	308
Won Seon Bang South Korea	9	256 0.8×	40 0.3×	224 1.8×	61 0.9×	124 3.1×	10	386
Tomoko Funazo Japan	10	223 0.7×	172 1.4×	56 0.5×	62 0.9×	123 3.1×	28	347
Takashi Nomizo Japan	11	236 0.8×	175 1.4×	57 0.5×	64 0.9×	124 3.1×	28	354
Linhda Nguyen United States	4	202 0.6×	35 0.3×	149 1.2×	56 0.8×	133 3.3×	5	326
Farkhondeh Movahedian Attar Switzerland	2	292 0.9×	54 0.4×	225 1.8×	28 0.4×	43 1.1×	3	364
Jeffrey C. Roeser United States	5	276 0.9×	40 0.3×	192 1.5×	53 0.7×	119 3.0×	9	392

Countries citing papers authored by Dina Pietrangelo

Since Specialization

Citations

This map shows the geographic impact of Dina Pietrangelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dina Pietrangelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dina Pietrangelo more than expected).

Fields of papers citing papers by Dina Pietrangelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dina Pietrangelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dina Pietrangelo. The network helps show where Dina Pietrangelo may publish in the future.

Co-authorship network of co-authors of Dina Pietrangelo

This figure shows the co-authorship network connecting the top 25 collaborators of Dina Pietrangelo. A scholar is included among the top collaborators of Dina Pietrangelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dina Pietrangelo. Dina Pietrangelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Rugo, Hope S., Jean‐Pierre Delord, Seock‐Ah Im, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Cancer Research. 24(12). 2804–2811. 264 indexed citations

2.

Rugo, HS, J.P. Delord, S-A. Im, et al.. (2016). Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Research. 76(4_Supplement). S5–7. 77 indexed citations

3.

Siegel, David S., Sundar Jagannath, Roman Hájek, et al.. (2010). Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. Blood. 116(21). 1952–1952. 2 indexed citations

4.

Siegel, David S., Sundar Jagannath, Sagar Lonial, et al.. (2009). Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.. Blood. 114(22). 3890–3890. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact